One platform for all researcher needs
AI-powered academic writing assistant
Your #1 AI companion for literature search
AI tool for graphics, illustrations, and artwork
Unlock unlimited use of all AI tools with the Editage All Access membership.
Explore Editage All Access
Search from 250 M+ research papersSearch from 250 M+ research papers
Open Accesshttps://doi.org/10.1016/j.annonc.2023.09.2722
Copy DOI Journal: Annals of Oncology |  Publication Date: Oct 1, 2023 |
 Citations: 3 |
Affiliation: University Medical Center Freiburg, Seoul National University, MSD (United States), Istanbul University-Cerrahpaşa, Jingdong (China), Fiona Stanley Hospital, Urology Associates, Institut Català d'Oncologia, Duran i Reynals Hospital, Seoul National University Bundang Hospital, Ordensklinikum Linz Barmherzige Schwestern, AGO Austria, Rambam Health Care Campus, Hospital Civil de Guadalajara, Ankara Yıldırım Beyazıt University, Istituti di Ricovero e Cura a Carattere Scientifico, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, State Higher Vocational School in Koszalin, Rechts der Isar Hospital1772MO Pembrolizumab (pembro) plus enzalutamide (enza) and androgen deprivation therapy (ADT) for patients (pts) with metastatic hormone-sensitive prostate cancer (mHSPC): Randomized double-blind phase III KEYNOTE-991 study
Sign-in/Register to access full text options 
Free) Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
